Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Rhea-AI Summary

Dyadic Applied BioSolutions (NASDAQ: DYAI) and Inzymes ApS announced planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production after completing final development activities.

Dyadic received a $200,000 milestone payment and remains eligible for royalties on future commercial sales; the global dairy processing enzyme market is estimated at $1.5–$2.0 billion annually.

Positive

• Planned commercialization of non-animal chymosin in 2026
• Earned a $200,000 development milestone payment
• Eligible to receive royalties on future commercial sales
• Addresses a $1.5–$2.0B annual dairy enzyme market

Negative

• Only $200,000 received to date—no reported commercial revenue yet
• Commercial impact depends on future product adoption and sales

News Market Reaction – DYAI

-1.68%

1 alert

-1.68% News Effect

On the day this news was published, DYAI declined 1.68%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Milestone payment: $200,000 Dairy enzymes market: $1.5–$2.0 billion annually Commercialization target year: 2026 +1 more

4 metrics

Milestone payment $200,000 Payment earned upon completion of development activities with Inzymes

Dairy enzymes market $1.5–$2.0 billion annually Estimated global market for dairy processing enzymes

Commercialization target year 2026 Planned commercialization of recombinant non-animal bovine chymosin

Collaboration agreement year 2023 Development and commercialization agreement for non-animal dairy enzymes

Market Reality Check

Price: $0.7892 Vol: Volume 73,149 vs 20-day a...

high vol

$0.7892 Last Close

Volume Volume 73,149 vs 20-day average 41,254 (relative volume 1.77x) ahead of the news. high

Technical Shares at $0.779, trading below the $0.97 200-day MA and 49.74% under the 52-week high.

Peers on Argus

DYAI was modestly down 0.15% while 3 sector peers (RANI, ESLA, CLGN) also moved ...

3 Down

DYAI was modestly down 0.15% while 3 sector peers (RANI, ESLA, CLGN) also moved down ~5–6%, indicating broader biotech pressure rather than a company-specific move.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Product launch	Positive	-3.0%	Commercial launch of recombinant human albumin with profit-sharing from Proliant.
Dec 17	Partnership expansion	Positive	-1.4%	Expanded Fermbox Bio collaboration for manufacturing and co-commercialization of proteins.
Dec 15	Commercial partnership	Positive	-9.3%	Agreement with Opes Diagnostics to commercialize recombinant growth factors and media proteins.
Dec 01	Development deal	Positive	-1.8%	Development and commercialization agreement for bovine alpha-lactalbumin with BRIG BIO.
Nov 12	Earnings update	Negative	-3.9%	Q3 2025 report with lower revenue and a wider net loss versus prior year.

Pattern Detected

Recent DYAI news has often been followed by share price declines, even on positive commercial and partnership updates, with only the negative Q3 earnings release aligning directionally.

Recent Company History

Over the last several months, Dyadic announced multiple commercial and partnership milestones, including the Feb 17, 2026 commercial launch of recombinant human albumin with Proliant, expanded collaboration with Fermbox Bio on Dec 17, 2025, and a commercial partnership with Opes Diagnostics on Dec 15, 2025. A BRIG BIO development and commercialization deal for bovine alpha-lactalbumin was signed on Dec 1, 2025. Q3 2025 results on Nov 12, 2025 showed lower revenue and a wider net loss. Despite mostly positive operational news, shares typically traded lower after these announcements.

Market Pulse Summary

This announcement confirms completion of final development work for recombinant non-animal bovine ch...

Analysis

This announcement confirms completion of final development work for recombinant non-animal bovine chymosin and a $200,000 milestone payment under the Inzymes collaboration, with commercialization targeted for 2026. It expands Dyadic’s presence in the non-animal dairy enzyme space, addressing a $1.5–$2.0 billion global market. In context of prior launches and partnerships, investors may watch how quickly this translates into recurring royalties, overall revenue growth, and progress on broader food and nutrition enzyme pipelines.

Key Terms

recombinant, chymosin, microbial expression platforms, fermentation-derived

4 terms

recombinant technical

"announced the planned 2026 commercialization of recombinant non-animal bovine chymosin"

Recombinant describes a product made by combining genetic material from different sources so cells can be used as tiny factories to produce a desired protein, vaccine ingredient or enzyme. For investors, the label signals a biotechnology approach that can enable scalable manufacturing, patent protection and targeted therapies, but also brings specific regulatory review, production complexity and clinical risk — similar to a customized recipe that can yield high value but needs precise execution.

chymosin medical

"recombinant non-animal bovine chymosin, a key enzyme used in cheese production"

Chymosin is a natural enzyme that causes milk to thicken and separate into curds and whey, a key step in cheese-making. Think of it as the ingredient that tells milk to turn into cheese; it can come from animal stomachs or be made with microbes using biotech. For investors, chymosin matters because its source, cost, labeling and regulatory approval affect cheese producers' margins, supply chains and product claims, and can influence valuations of food and biotech firms.

microbial expression platforms technical

"produced using Dyadic’s proprietary microbial expression platforms"

Microbial expression platforms use living microbes such as bacteria or yeast as miniature factories to produce proteins, enzymes, vaccines or other biological molecules needed for drugs, diagnostics and industrial products. Investors care because these platforms determine how cheaply and quickly a company can scale production, meet quality and regulatory standards, and protect intellectual property — much like choosing an efficient assembly line affects a factory’s cost, speed and reliability.

fermentation-derived technical

"demand for sustainable, fermentation-derived alternatives to traditional animal-sourced enzymes"

Products described as fermentation-derived are made by feeding simple ingredients to microbes or yeast so those tiny organisms produce a desired ingredient—think of it like brewing beer but for proteins, enzymes, or other molecules. Investors care because this method can lower costs, scale supply, and reduce reliance on traditional manufacturing or crops, affecting profit margins, regulatory review, and a company’s ability to meet demand quickly.

AI-generated analysis. Not financial advice.

JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS (“Inzymes”), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion of final development activities under the companies’ collaboration agreement.

Completion of these development activities represents a contractual milestone under the parties’ 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using Dyadic’s proprietary microbial expression platforms. With achievement of this milestone, Dyadic has earned and received a $200,000 milestone payment and remains eligible to receive royalties on future commercial sales.

Chymosin is the primary milk-clotting enzyme used in cheese manufacturing. The global market for dairy processing enzymes is estimated to be approximately $1.5–$2.0 billion annually, driven by increasing global cheese consumption and rising demand for sustainable, fermentation-derived alternatives to traditional animal-sourced enzymes.

“This milestone reflects the strength of our partnership with Dyadic and our shared commitment to delivering innovative, sustainable enzyme solutions to the dairy industry,” said Michael Fooken Jensen, CEO of Inzymes ApS. “With final development activities successfully completed, we are advancing with preparations for commercialization in 2026. By combining Dyadic’s high-productivity microbial platforms with our scale-up and commercialization expertise, we are positioning this non-animal chymosin to meet evolving customer requirements for performance, consistency, and supply reliability.”

Joe Hazelton, President and COO of Dyadic Applied BioSolutions, stated: “The achievement of this development milestone marks important progress under our agreement with Inzymes and demonstrates our ability to advance programs from development through commercialization. We believe our microbial expression platforms support efficient development and scalable manufacturing, and we look forward to expanding into additional enzyme and protein opportunities across our business segments.”

Additional non-animal dairy enzyme candidates continue to progress under the collaboration, supporting expansion of the companies’ portfolio within the growing market for fermentation-derived food enzymes. The successful completion of final development steps toward commercialization further reinforces the versatility of Dyadic’s platforms across food and nutrition, life sciences, and industrial biotechnology applications.

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com.

About Inzymes ApS

Inzymes ApS is a Denmark-based enzyme innovation company focused on the development, scale-up, and commercialization of high-performance enzymes for food and beverage applications. Leveraging expertise in fermentation, formulation, and industrial enzyme deployment, Inzymes partners across the value chain to deliver sustainable, food-grade enzyme solutions that improve functionality, efficiency, and product quality. The company is committed to advancing next-generation bioprocessing technologies that support a more sustainable global food system. For more information please visit www.inzymes.com.

Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.

Media contacts:

Dyadic Applied BioSolutions:
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com

Inzymes ApS:
Michael Fooken Jensen
Email: michael@inzymes.com

FAQ

What did Dyadic (DYAI) and Inzymes announce about non-animal chymosin commercialization in 2026?

They plan commercialization of recombinant non-animal bovine chymosin in 2026, following completed final development activities. According to the company, this milestone concluded the collaboration's final development steps and moves the product toward market launch.

How much did Dyadic (DYAI) receive after achieving the development milestone with Inzymes?

Dyadic received a $200,000 milestone payment upon milestone completion. According to the company, Dyadic also remains eligible to receive royalties on any future commercial sales of the enzyme.

What is the market size for dairy processing enzymes relevant to Dyadic's (DYAI) chymosin?

The global dairy processing enzyme market is estimated at about $1.5–$2.0 billion annually. According to the company, demand is driven by rising cheese consumption and interest in fermentation-derived, animal-free alternatives.

Will Dyadic (DYAI) earn royalties from the commercial sales of the non-animal chymosin?

Yes, Dyadic remains eligible to receive royalties on future commercial sales of the enzyme. According to the company, the milestone achievement preserves Dyadic's royalty rights under the collaboration agreement.

What role does Dyadic's technology play in the Inzymes collaboration for DYAI shareholders?

Dyadic's microbial expression platforms supported development and scalable manufacturing of the enzyme. According to the company, this technology underpins efficiency and potential expansion into additional enzymes and proteins.

What is the timeline and next step for commercial availability of the non-animal chymosin from Dyadic (DYAI)?

Commercialization preparations are underway for 2026, aiming for market launch next year. According to the company, final development completion enables commercial-scale preparations and go-to-market activities.